AU6543286A - Method of using bar1 for secreting foreign proteins - Google Patents

Method of using bar1 for secreting foreign proteins

Info

Publication number
AU6543286A
AU6543286A AU65432/86A AU6543286A AU6543286A AU 6543286 A AU6543286 A AU 6543286A AU 65432/86 A AU65432/86 A AU 65432/86A AU 6543286 A AU6543286 A AU 6543286A AU 6543286 A AU6543286 A AU 6543286A
Authority
AU
Australia
Prior art keywords
barl
promoter
fragment
gene
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65432/86A
Other languages
English (en)
Inventor
Vivian L. Mackay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of AU6543286A publication Critical patent/AU6543286A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU65432/86A 1985-10-25 1986-10-20 Method of using bar1 for secreting foreign proteins Abandoned AU6543286A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79130585A 1985-10-25 1985-10-25
US791305 1985-10-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU74003/91A Division AU676132B2 (en) 1985-10-25 1991-04-02 Method of using bar1 for secreting foreign proteins

Publications (1)

Publication Number Publication Date
AU6543286A true AU6543286A (en) 1987-05-19

Family

ID=25153298

Family Applications (2)

Application Number Title Priority Date Filing Date
AU65432/86A Abandoned AU6543286A (en) 1985-10-25 1986-10-20 Method of using bar1 for secreting foreign proteins
AU74003/91A Ceased AU676132B2 (en) 1985-10-25 1991-04-02 Method of using bar1 for secreting foreign proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU74003/91A Ceased AU676132B2 (en) 1985-10-25 1991-04-02 Method of using bar1 for secreting foreign proteins

Country Status (13)

Country Link
EP (1) EP0243465A1 (fr)
JP (1) JP2523562B2 (fr)
CN (1) CN1027179C (fr)
AU (2) AU6543286A (fr)
CA (1) CA1316133C (fr)
CZ (1) CZ284251B6 (fr)
DK (1) DK320287D0 (fr)
FI (1) FI872801A0 (fr)
HU (1) HU206897B (fr)
IE (1) IE63822B1 (fr)
SK (1) SK776486A3 (fr)
UA (1) UA41863C2 (fr)
WO (1) WO1987002670A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU590197B2 (en) * 1984-05-30 1989-11-02 Novo Nordisk A/S Insulin precursors, process for their preparation and process for preparing human insulin from such insulin precursors
AU633020B2 (en) * 1988-07-23 1993-01-21 Novozymes Delta Limited New secretory leader sequences
AU660172B2 (en) * 1987-10-02 1995-06-15 Zymogenetics Inc. BAR1 secretion signal

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206699A (en) * 1988-05-06 1993-04-27 Gersan Establishment Sensing a narrow frequency band of radiation and gemstones
WO1991013971A1 (fr) * 1990-03-13 1991-09-19 Hawaii Biotechnology Group, Inc. SYSTEME D'EXPRESSION A $i(NEUROSPORA)
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
MX9706974A (es) 1995-03-17 1997-11-29 Novo Nordisk As Endoglucanasas novedosas.
AU710818B2 (en) 1996-03-01 1999-09-30 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
AR027509A1 (es) 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
ES2325877T3 (es) 2000-02-11 2009-09-23 Bayer Healthcare Llc Moleculas de tipo factor vii o viia.
EP1366075B1 (fr) 2001-02-27 2009-05-27 Maxygen Aps Nouvelles molecules de type interferon beta
CA2441580A1 (fr) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Derives du facteur vii de coagulation
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
CZ2004427A3 (cs) 2001-09-27 2004-08-18 Novoánordiskáhealthácareáag Polypeptidy lidského koagulačního faktoru VII
EP2392655A3 (fr) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Polypeptides de facteur VII à coagulation
MX2007012887A (es) 2005-04-18 2007-12-10 Novo Nordisk As Variantes il-21.
EP1917363B1 (fr) 2005-08-16 2011-06-22 Novo Nordisk A/S Procede permettant de realiser des polypeptides d'insuline matures
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
CN101501216B (zh) 2006-03-06 2013-10-02 胡玛基因公司 制备重组人凝血酶的方法
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
ES2464282T3 (es) 2006-09-27 2014-06-02 Novo Nordisk A/S Método para preparar polipéptidos de insulina madura
BRPI0810622A2 (pt) 2007-05-02 2020-10-13 Ambrx, Inc. polipeptídeos de interferon beta modificados e seus usos
CN101918026B (zh) 2007-11-20 2016-03-02 Ambrx公司 经修饰胰岛素多肽和其用途
UA103774C2 (uk) 2008-07-23 2013-11-25 Амбркс, Інк. Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
WO2010103038A1 (fr) 2009-03-11 2010-09-16 Novo Nordisk A/S Variants de l'interleukine 21 se liant de manière antagoniste au récepteur de l'il-21
CN102712687A (zh) 2009-07-17 2012-10-03 丹麦国家医院 作为补体激活的抑制剂的masp同种型
WO2011067283A1 (fr) 2009-12-01 2011-06-09 Novo Nordisk A/S Nouvelles peptidyl a-hydroxyglycine a-amide lyases
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
CA2791841C (fr) 2010-03-05 2023-01-03 Rigshospitalet Molecules chimeriques inhibitrices d'activation du complement
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
WO2011163558A1 (fr) 2010-06-25 2011-12-29 Abbott Laboratories Matériaux et procédés pour le dosage d'anticorps anti-virus de l'hépatite c (hvc)
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
CA2819552C (fr) 2010-12-09 2023-09-26 Institut Pasteur Procede a base de mgmt permettant d'obtenir une expression elevee de proteines recombinees
WO2013083847A2 (fr) 2011-12-09 2013-06-13 Institut Pasteur Immunoessai de dépistage multiplex
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
SG10201606195UA (en) 2012-02-09 2016-09-29 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
JP2015532307A (ja) 2012-10-15 2015-11-09 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 凝固因子ｖｉｉポリペプチド
JP2014128262A (ja) * 2012-11-27 2014-07-10 Kirin Brewery Co Ltd 接合能を持つ酵母細胞株のスクリーニング方法
AU2019263303A1 (en) 2018-05-01 2020-12-24 Ambrx, Inc. A method for optimizing antibody expression
US20210278406A1 (en) 2018-07-13 2021-09-09 Varct Diagnostic Aps Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
PT3849614T (pt) 2018-09-11 2024-02-28 Ambrx Inc Conjugados de polipeptídeos de interleucina-2 e suas utilizações
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
US20220226488A1 (en) 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
JP2023517595A (ja) 2020-03-11 2023-04-26 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド結合物およびその使用方法
EP4136459A1 (fr) 2020-04-13 2023-02-22 Abbott Laboratories Procédés, complexes et kits pour détecter ou déterminer une quantité d'un anticorps anti-ss-coronavirus dans un échantillon
WO2022031804A1 (fr) 2020-08-04 2022-02-10 Abbott Laboratories Méthodes et kits améliorés pour détecter une protéine sars-cov-2 dans un échantillon
KR20230073200A (ko) 2020-08-20 2023-05-25 암브룩스, 인코포레이티드 항체-tlr 작용제 접합체, 그 방법 및 용도
EP4271998A1 (fr) 2020-12-30 2023-11-08 Abbott Laboratories Procédés pour déterminer un antigène sras-cov-2 et anticorps anti-sras-cov-2 dans un échantillon
JP2024512775A (ja) 2021-04-03 2024-03-19 アンブルックス，インコーポレイテッド 抗ｈｅｒ２抗体薬物コンジュゲート及びその使用
CN115806889A (zh) * 2022-09-28 2023-03-17 山东大学 一种提高基因表达水平的酿酒酵母工程菌及其构建方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4613572A (en) * 1983-08-15 1986-09-23 Kansas State University Research Foundation Yeast BAR1 gene plasmid
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
JPS61247384A (ja) * 1984-10-18 1986-11-04 チモ−ジエネテイツクス　インコ−ポレ−テツド 酵母中でプラスミノ−ゲン活性化因子を発現する方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU590197B2 (en) * 1984-05-30 1989-11-02 Novo Nordisk A/S Insulin precursors, process for their preparation and process for preparing human insulin from such insulin precursors
AU660172B2 (en) * 1987-10-02 1995-06-15 Zymogenetics Inc. BAR1 secretion signal
AU633020B2 (en) * 1988-07-23 1993-01-21 Novozymes Delta Limited New secretory leader sequences

Also Published As

Publication number Publication date
EP0243465A1 (fr) 1987-11-04
HU206897B (en) 1993-01-28
UA41863C2 (uk) 2001-10-15
FI872801A (fi) 1987-06-24
CN1027179C (zh) 1994-12-28
CZ776486A3 (en) 1996-09-11
AU7400391A (en) 1991-07-18
DK320287A (da) 1987-06-23
CA1316133C (fr) 1993-04-13
CN86107554A (zh) 1987-08-26
IE63822B1 (en) 1995-06-14
CZ284251B6 (cs) 1998-10-14
FI872801A0 (fi) 1987-06-24
WO1987002670A1 (fr) 1987-05-07
AU676132B2 (en) 1997-03-06
JPS63501614A (ja) 1988-06-23
IE862804L (en) 1987-04-25
SK279041B6 (sk) 1998-06-03
DK320287D0 (da) 1987-06-23
JP2523562B2 (ja) 1996-08-14
HUT43624A (en) 1987-11-30
SK776486A3 (en) 1998-06-03

Similar Documents

Publication Publication Date Title
CA1316133C (fr) Methodes d'utilisation du gene bar1 pour la secretion de proteines etrangeres
CA1340772C (fr) Expression et secretion de proteines heterologues dans une levure au moyen de sequences leader tronquees du facteur alpha
US5037743A (en) BAR1 secretion signal
CA1340547C (fr) Nouvelles sequences-guides de secretion pour levures
EP0123544A2 (fr) Procédé d'expression de protéines hétérologues dans les levures, vecteurs d'expression et micro-organismes du genre levure à cet effet
CA2090969C (fr) Production de facteur de croissance insulinoide dans les cellules de levure methylotrophiques
US4588684A (en) a-Factor and its processing signals
CA2085308C (fr) Endoprotease dibasique fusionne au signal de retention reticulum endoplasmique et utilisation
US5612198A (en) Production of insulin-like growth factor-1 in methylotrophic yeast cells
EP0220689B1 (fr) Méthode permettant l'utilisation de BAR1 pour la sécrétion de protéines étrangères
JP3135550B2 (ja) 成熟異種タンパク質、特にヒルジン、の製造のための改良された酵母株、および対応するヒルジンの製造法
JP4180112B2 (ja) 酵母細胞におけるｎ末端を伸長されたタンパクの発現のためのベクター
US7198919B1 (en) Use of alpha factor sequences in yeast expression systems
EP0310137B1 (fr) Séquence signal BAR1
US5879926A (en) Yeast strains for the production of mature heterologous proteins, especially hirudin
EP1097228B1 (fr) Technique de production de proteines dans des cellules de levure transformees
WO1991002057A1 (fr) Production de polypeptides a l'interieur de cellules fongiques